Want to see NSPR full AI Analyst Report?
Top Page
InspireMD
(NASDAQ:NSPR)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.88
▲(29.26% Upside)
Action:Reiterated
Date:08/18/26
Overall score is held down primarily by weak financial performance (deep operating losses and substantial cash burn) despite low leverage. Technical indicators show improving near-term momentum, and the earnings call provides meaningful regulatory catalysts plus cost-cutting, but recall impacts and the large cash decline keep the risk profile elevated. Valuation contributes limited support due to negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
International Revenue Growth
International growth despite the U.S. commercial pause indicates continued physician adoption and demand for CGuard in overseas markets. This geographic traction can diversify revenue and provide a foundation for broader expansion as U.S. products return to market.
Negative Factors
Severe Cash Burn
Persistent negative operating and free cash flow means the business is not self-funding. Continued clinical, regulatory and commercial spending could require additional financing before approvals generate meaningful revenue, creating liquidity and potential dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
International Revenue Growth
International growth despite the U.S. commercial pause indicates continued physician adoption and demand for CGuard in overseas markets. This geographic traction can diversify revenue and provide a foundation for broader expansion as U.S. products return to market.
Read all positive factors
InspireMD Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Breaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Data provided by:
The Fly
The FlyInspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.01M
Dividend YieldN/A
Average Volume (3M)102.59K
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth53.42%
EPS Growth22.08%
CountryUS
Employees127
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.50
Shares Outstanding46,489,117
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside414.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$10.38M
InspireMD Business Overview & Revenue Model
Company Description
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to add...
How the Company Makes Money
InspireMD’s primary revenue model is product-based: it generates revenue by selling its vascular medical devices to healthcare providers (e.g., hospitals and interventional centers) through direct sales and/or distribution partners, depending on t...
InspireMD Earnings Call Summary
Earnings Call Date:Aug 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Neutral
The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.Positive Updates
Stable Total Revenue Year‑over‑Year
Total revenue of $1.8 million in Q2 2026 was essentially unchanged versus Q2 2025 (flat YoY), despite a temporary U.S. commercial pause due to the voluntary recall.
Negative Updates
Voluntary Recall Impacted Reported Results
Voluntary recall of CGuard Prime 135 delivery system led to U.S. commercial pause (less than one month of U.S. sales in Q2), a $734,000 customer credit booked in Q2 and a $612,000 inventory impairment for product no longer commercially viable, which materially impacted reported revenue and gross margin.
Read all updates
Q2-2026 Updates
Positive
Negative
Stable Total Revenue Year‑over‑Year
Total revenue of $1.8 million in Q2 2026 was essentially unchanged versus Q2 2025 (flat YoY), despite a temporary U.S. commercial pause due to the voluntary recall.
Read all positive updates
Company Guidance
Management provided multi‑pronged guidance focused on regulatory and commercial milestones: potential FDA decisions in Q4 2026 for CGuard Prime 80 (TCAR) and the original CGuard CAS platform, targeted market re‑entry for the redesigned CGuard Prime 135 in H1 2027 (possible earlier approval), and a SwitchGuard pivotal program aiming toward a H2 2027 U.S. approval/launch; if approvals occur, the company expects to address roughly 75,000 annual U.S. stenting procedures and says Prime 80 would roughly double its addressable market. Financial and operational metrics/guidance included Q2 FY2026 results of total revenue $1.8M (international revenue $2.1M, +21% YoY), a Q2 gross loss of $0.8M (‑43.7% of revenue) driven by a $734k customer credit and $612k inventory impairment (adjusted non‑GAAP gross profit $0.6M), operating expenses $13.7M, net loss $14.3M (‑$0.17/share), cash & marketable securities $30.4M (6/30/26), a ~20% workforce reduction expected to save ~$9M annually with a Q3 restructuring charge of $0.9–1.2M, and most cost savings expected to be realized by Q4 2026.InspireMD Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.84M | 8.98M | 7.01M | 6.21M | 5.17M | 4.50M |
| Gross Profit | 1.96M | 2.65M | 1.51M | 1.81M | 1.12M | 754.00K |
| EBITDA | -37.88M | -48.25M | -31.67M | -19.62M | -18.27M | -14.55M |
| Net Income | -38.50M | -48.79M | -32.01M | -19.92M | -18.49M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 44.64M | 69.40M | 46.81M | 47.64M | 24.65M | 39.71M |
| Cash, Cash Equivalents and Short-Term Investments | 30.42M | 54.21M | 34.64M | 39.02M | 17.80M | 34.04M |
| Total Debt | 1.97M | 3.29M | 2.34M | 1.59M | 1.61M | 1.20M |
| Total Liabilities | 13.13M | 14.20M | 10.72M | 8.14M | 7.26M | 6.18M |
| Stockholders Equity | 31.51M | 55.20M | 36.09M | 39.50M | 17.39M | 33.53M |
Cash Flow | ||||||
| Free Cash Flow | -42.46M | -36.77M | -23.27M | -16.76M | -16.02M | -13.55M |
| Operating Cash Flow | -41.21M | -35.10M | -21.87M | -16.38M | -15.54M | -13.21M |
| Investing Cash Flow | -8.15M | -30.56M | 12.64M | -16.09M | 8.44M | -22.46M |
| Financing Cash Flow | 52.93M | 55.57M | 18.45M | 37.53M | -140.00K | 35.03M |
InspireMD Technical Analysis
Positive
0.68
Price Trends
0.73
Positive
0.98
Negative
1.40
Negative
Market Momentum
0.04
Negative
62.42
Neutral
78.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 0.68 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.73, and below the 200-day MA of 1.40, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 62.42 is Neutral, neither overbought nor oversold. The STOCH value of 78.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.
InspireMD Risk Analysis
InspireMD disclosed 46 risk factors in its most recent earnings report. InspireMD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InspireMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $287.73M | -79.67 | -2.70% | ― | -2.50% | 93.57% | |
53 Neutral | $127.64M | -14.80 | -78.70% | ― | 25.59% | 55.35% | |
52 Neutral | $126.28M | -3.86 | -191.05% | ― | ― | 19.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $46.01M | -1.77 | -81.52% | ― | 53.42% | 22.08% | |
44 Neutral | $42.79M | -4.03 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
NSPR
InspireMD
0.88
-1.61
-64.70%
ANIK
Anika Therapeutics
21.47
12.78
147.07%
APYX
Apyx Medical
3.06
0.92
42.99%
VANI
Vivani Medical
1.35
0.11
8.87%
XTNT
Xtant Medical Holdings
0.33
-0.32
-49.00%
InspireMD Corporate Events
Business Operations and StrategyExecutive/Board Changes
InspireMD Eliminates Chief Commercial Officer Position
Negative
Jul 29, 2026
On July 23, 2026, InspireMD, Inc. notified Chief Commercial Officer Shane Gleason that his position had been eliminated. His employment with the company is scheduled to end on July 31, 2026.The removal of the CCO role marks a notable change in Ins...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
InspireMD Receives Nasdaq Notice on Bid Price Compliance
Negative
Jul 23, 2026
On July 17, 2026, InspireMD, Inc. disclosed that it received a notice from Nasdaq stating its shares no longer meet the minimum $1.00 bid price requirement, after trading below that threshold for 30 consecutive business days ending July 16, 2026. ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial
Positive
Jun 11, 2026
On June 11, 2026, InspireMD reported 30-day outcomes from its CGUARDIANS II clinical trial evaluating the investigational CGuard Prime 80 cm carotid stent for use in TCAR procedures, showing 100% acute device success across 50 patients, with no de...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
InspireMD Shareholders Approve Stock Increase and Board Slate
Positive
Jun 3, 2026
At its annual meeting held on June 3, 2026, InspireMD shareholders re-elected directors Marvin Slosman, Raymond Cohen and Dan Dearen as Class 3 directors to new three-year terms, with a quorum of 73.85% of outstanding shares represented. Stockhold...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.